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▼Mutations very near to the 5′ or 3′ end (up to ∼ 40 bp)
of a target sequence are easy to introduce directly by a one-
step PCR protocol using mismatching primers. However, it
is more difficult in a one-step PCR protocol to introduce
mutations large distances from the ends of the DNA tem-
plate and to obtain a full-length PCR product avoiding ran-
dommutations created during the polymerization reaction
(Ref. 1). To circumvent such problems, it is necessary to
perform the in vitro mutagenesis in a two-stage PCR reac-
tion using a polymerase such as Pwo polymerase which has
proofreading activity instead of a conventional Taq poly-
merase. Two-stage PCR mutagenesis methods based on at
least one useful restriction site in close proximity to the tar-
get nucleotide sequence (Ref. 2) ormethods which use over-
lap extension in a second PCR step (Ref. 3, 4) always need
a set of four primers. Previously described one-step−three-
stage or one-tube methods often require special equipment
or additional working steps. For example, when using bi-
otinylated primers, classical avidin-coated beads cannot be
used as they inactivate the Pwo polymerase and so spe-
cial encapsulated magnetic beads which are more expen-
sive must be used instead (Ref. 5). Other published proto-
cols specify elaborate stages which could be elimated, such
as Geneclean purification of megaprimers (Ref. 6), ddNTP-
blocked DNA as template in the first PCR step (Ref. 7) to
prevent wild-type amplification or the toleration of wild-
type amplification because of imbalanced primer relation
(Ref. 8) or imbalanced cycling parameters which should be
optimized for eachmutagenesis (Ref. 7). The treatment with
Taq polymerase and dATP to add 3′ protruding adenosine
to both ends of the product to be cloned in an TA Cloning
Kit vector is also unnecessary (Ref. 7).
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We describe here a novel and simple one-tube, two-stage
PCR mutagenesis method with only one mutagenic primer
in addition to the upstream and downstream primers and
without any separation or purification steps.
In the first stage, the 3′ specific primer and the inter-
nal 5′ mutagenic primer generate a double stranded, mu-
tated fragment (1a and 1b in Figures 1 and 2). This in vitro
synthesized fragment carrying the mutation is used as a
megaprimer together with the 5′ specific primer in the sec-
ond stage PCR to obtain the desired mutated fragment (2a
and 2b in Figures 1 and 2).
To avoid both wild-type amplification and purification
steps we simply used an excess of the 5′ mutagenic primer
in the first PCR stage and of the 5′ specific primer in the sec-
ond PCR stage and allowed a complete reaction in both PCR
stages (Fig. 1). Because of the exhaustion of the 3′ specific
primer in the first stage and the megaprimer in the second
stage, the wild-type background as well as the cloning of
the megaprimer as PCR product are nearly excluded. The
use of Pwo polymerase ensures that the mutated final prod-
uct is blunt ended. We have very good experiences with
the Zero Blunt PCR Cloning Kit (Invitrogen). It has two
advantages. First, there is the possibility of direct cloning
of the blunt-ended product with high efficiency. Second,
it offers a zero background due to the lacZ−ccdB(control of
cell death) gene fusion, permitting growth of only positive
recombinants upon transfection. Cells that contain non-
recombinant vectors are killed when the transformation
mixture is plated.
First PCR stage
PCR was performed according to standard protocols de-
scribed elsewhere (Ref. 1) but with somemodifications: only
20 cycles in 25 µl 1× PCR buffer containing as template
100 ng of uncut plasmid DNA including the target
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FIGURE 1. In the first PCR stage, using a 3′ specific primer and an excess of the mutagenic 5′ primer, a mutated intermediate PCR product
(megaprimer) is amplified. In the second PCR stage, this megaprimer is used together with an excess of specific 5′ primer to achieve the desired mutated
product. This figure shows the use of alternative 5′ mutagenic primers in separate experiments, giving rise to two alternative mutated intermediate PCR
products of different lengths (1a and 1b). However, both of these result in full-length mutated PCR products after the second stage, since the length of the
second PCR product is determined by the 3′ and 5′ specific primers.
sequence, an excess of 50 pmol mutagenic primer, 25 pmol
3′ specific primer, 2.5 U Pwo polymerase and 200µMof each
dNTP were used. We used a thermal cycler with a heated
lid to prevent evaporation in the reaction tubes. Each cy-
cle consisted of 30 s at 94◦C (denaturation), 60 s at 60◦C
(annealing) and 30 s at 72◦C (polymerization).
Second PCR stage
The second PCR stage was performed as described for the
first stage. A previously prepared mixture of 100 pmol 5′
specific primer, 2.5 U Pwo polymerase, 200 µM dNTPs in
25 µl 1× PCR buffer was added to the reaction following
the first stage. The intermediate fragment from the first
PCR step (1a or 1b in Figure 1) was used as megaprimer
in combination with an excess of the 5′ specific primer.
Given that the set-up time for reactions is about 30 min
and both PCR stages require about 70 min, the PCR part
of the mutagenesis procedure is completed in less than
3 h.
Cloning
Direct cloning of Pwo polymerase PCR products with the
Zero Blunt PCR Cloning Kit (Invitrogen) is very simple and
highly efficient. The cloning procedure was performed ac-
cording to Invitrogen’s manual. We obtained a sufficient
number of transformants one day after mutagenesis. Be-
cause wild-type background is almost at zero in the PCR
stages and is prevented during the subcloning by the lethal
ccdB gene, it is unneccessary to purify the PCR product or
to check a large number of transformants.
We have successfully performed over 10 different mu-
tagenesis experiments with megaprimers from 109 bp to
536 bp with this method (see example in Figure 2). We
routinely analyze six subclones for each mutagenesis and
usually all of them contain the correct insertion and mu-
tation. This shows the high efficiency of using an excess
of 5′ primer. In cases where the mutagenic primers lead
to restriction site changes, we checked the subclones first
with restriction analysis, otherwise we analyzed a subclone
with the correct insertion size by sequencing. If the desired
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FIGURE 2. Gel analysis of two separate mutagenesis experiments using different 5′ mutagenic primers in the first stage PCR (which give rise to
differently sized mutagenic 3′ megaprimers) but identical 39 nt 5′ specific primers in the second PCR stage. Lane 1, DNA markers (Boehringer Mannheim)
V; lanes 2 and 3, mutated intermediate products of the first stage PCR (1b, 224 bp and 1a, 109 bp, respectively); lanes 4 and 5, mutated full length (750
bp) products of the second PCR stage (2b and 2a, respectively); lanes 6 and 7, PCR products 2b and 2a (respectively) cloned in the pZero Blunt vector;
lane 8, DNA markers (Boehringer Mannheim) III.
mutation was confirmed by sequencing over the mutated
region, this subclone was sequenced completely to exclude
random mutations caused by PCR. Such checks are impor-
tant for absolute reliability in expression studies. However,
the use of Pwo polymerase avoids most of these problems.
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Zero Blunt PCR Cloning Kit: Zero Blunt PCR
Cloning Kit from Invitrogen
Zero Blunt PCR Cloning Kit: Zero Blunt PCR
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